List of Restasis drug patents

Restasis is owned by Allergan.

Restasis contains Cyclosporine.

Restasis has a total of 10 drug patents out of which 0 drug patents have expired.

Restasis was authorised for market use on 23 December, 2002.

Restasis is available in emulsion;ophthalmic dosage forms.

Restasis can be used as increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)., increase tear production in patients with keratoconjunctivitis sicca (dry eye)..

The generics of Restasis are possible to be released after 11 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8292129 ALLERGAN Dispensing device
Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device
Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in